In short, while clinical topical administration of TRPM8 agonists is described to relief several types of pain, including inflammatory and mechanical painful processes, as well as migraine and some peripheral neuropathies, oral treatments with both agonists and antagonists produced important secondary effects that still preclude their progression into the clinic. The gene discussed is TRPM8; the disease is peripheral neuropathy.